Zhang, Xiaomeng
Nantong University · Nantong Tumor Hospital · Nanjing Sanhome Pharmaceutical Co., Ltd. (China)
2 papers on CoChatORCID 0000-0003-2504-8599
Most cited papers
- Verified
SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
Han, L., Zhang, X., Wang, Z., Zhang, X., Zhao, L., Fu, W., Liang, X., Zhang, Z., & Wang, Y. (2021) · Frontiers in Pharmacology
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 31
- Verified
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial
Xiong, A., Ren, S., Liu, H., Miao, L., Wang, L., Chen, J., Li, W., Li, R., Wang, X., Lu, Z., et al. (2022) · Journal of Thoracic Oncology
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 20
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free